Home Newsfeeds Baird Downgrades Under Armour to Neutral, Announces $10 Price Target

Baird Downgrades Under Armour to Neutral, Announces $10 Price Target

Baird analyst Jonathan Komp downgrades Under Armour (NYSE:UAA) from Outperform to Neutral and announces $10 price target.

byBenzinga Newsdesk

August 4, 2022

1 minute read

Baird analyst Jonathan Komp downgrades Under Armour (NYSE:UAA) from Outperform to Neutral and announces $10 price target.

News

New Shopify And Google Cloud AI Integration Brings Advanced Ecommerce Capabilities To Retailers And Merchants Worldwide

By Happy Mohamed

March 23, 9:04 AM

Shopify merchants can now deploy advanced search and browse experiences using Google Cloud's Discovery AI solution; Rainbow Shops the first to see success New research finds that search abandonment—when a

GOOG

Why Chimerix Stock Is Soaring Today

By Adam Eckert

August 29, 11:29 AM

Chimerix Inc (NASDAQ: CMRX) shares are trading higher Monday after the company won a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response.

CMRX

EMA’s Human Medicines Committee Has Started A Review Of The Medicine Ocaliva; Study 747-302 Failed To Show That Ocaliva Was More Effective Than Placebo, Additionally, Side Effects, Including Serious Ones, Occurred More Frequently In Patients

By Benzinga Newsdesk

October 13, 3:57 PM

https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-review-ocaliva-started_en.pdf Review of Ocaliva started EMA's human medicines committee (CHMP) has started a review of the medicine

ICPT